CASI Pharmaceuticals, Inc.
CASIF · PNK
Company research
CASI Pharmaceuticals, Inc. (CASIF) is a clinical-stage biopharmaceutical company incorporated in the Cayman Islands and headquartered in Beijing, China, focused on developing and commercializing innovative therapeutics and pharmaceutical products across China, the United States, and international markets. Founded in 1991, the company has a dual strategic focus encompassing hematology/oncology therapeutics — anchored by its commercial product EVOMELA, an intravenous melphalan formulation used in stem cell transplant conditioning and multiple myeloma palliative care — and the development of CID-103, a potential best-in-class human IgG1 anti-CD38 monoclonal antibody targeting organ transplant rejection and autoimmune diseases. Its broader pipeline includes investigative assets such as CNCT19 (an autologous CD19 CAR-T product), BI-1206 (an anti-FcγRIIB antibody), CB-5339 (a VCP/p97 inhibitor), and Thiotepa, supported by licensing agreements with partners including BioInvent International AB, Juventas Cell Therapy Ltd., and Acrotech Biopharma. With 233 full-time employees and operations in China conducted through its wholly owned subsidiary CASI Pharmaceuticals (China) Co., Ltd., the company leverages its China-based regulatory and commercial expertise alongside global drug development capabilities to address significant unmet medical needs.
Research reports
MarketBeat aggregates CASI’s valuation metrics, earnings history and analyst data, showing a micro‑cap with deeply negative profitability, a consensus “Hold” rating and a 4.00 USD price target that implies extreme upside from the current price, while accompanying news highlights listing extensions, product license issues and ongoing operational risks that make the investment case highly speculative.
Macroaxis · March 11, 2026CASI Pharmaceuticals (USA Stocks:CASI) Analysis & Price TodayMacroaxis delivers a quantitative, model‑driven profile of CASI emphasizing severe net losses, negative margins, rising liabilities and stressed profitability alongside a tiny nano‑cap valuation, and frames the stock through financial‑stability, debt‑structure, institutional‑holding and income‑statement dashboards without issuing an explicit buy or sell call, effectively underscoring substantial fundamental risk despite apparent cheapness on some ratios.
Simply Wall St · January 26, 2026CASI Pharmaceuticals (Nasdaq:CASI) Stock AnalysisSimply Wall St’s Snowflake‑based report rates CASI poorly on valuation, growth, past performance, financial health and dividends, highlights large share‑price declines versus U.S. biotech peers, and details weak earnings, thin gross margins and highly negative net profit margin and leverage metrics using standardized S&P‑sourced data, resulting in a clearly cautious view on the company’s investment appeal.
KoalaGains · November 2, 2025CASI Pharmaceuticals, Inc. (CASIF) Stock AnalysisKoalaGains’ qualitative equity report dissects CASI’s China‑focused in‑licensing and commercialization model, arguing the business has an exceptionally weak competitive moat, an extremely poor balance sheet with liabilities exceeding assets, rapid cash burn, constrained growth from a thin pipeline and intense competition, and concludes CASIF is a high‑risk stock best avoided until its financial health and business outlook improve materially.